Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squamous non-small-cell lung cancer

Trial Profile

A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squamous non-small-cell lung cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 24 Jan 2019 Planned number of patients changed from 40 to 45.
    • 24 Jan 2019 Planned primary completion date changed from 21 Jan 2021 to 25 Jan 2021.
    • 03 Dec 2018 Planned End Date changed from 21 Jan 2021 to 25 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top